» Articles » PMID: 30881381

Using Whole Genome Sequencing in an African Subphenotype of Myasthenia Gravis to Generate a Pathogenetic Hypothesis

Overview
Journal Front Genet
Date 2019 Mar 19
PMID 30881381
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Myasthenia gravis (MG) is a rare, treatable antibody-mediated disease which is characterized by muscle weakness. The pathogenic antibodies are most frequently directed at the acetylcholine receptors (AChRs) at the skeletal muscle endplate. An ophthalmoplegic subphenotype of MG (OP-MG), which is characterized by treatment resistant weakness of the extraocular muscles (EOMs), occurs in a proportion of myasthenics with juvenile symptom onset and African genetic ancestry. Since the pathogenetic mechanism(s) underlying OP-MG is unknown, the aim of this study was to use a hypothesis-generating genome-wide analysis to identify candidate OP-MG susceptibility genes and pathways. Whole genome sequencing (WGS) was performed on 25 AChR-antibody positive myasthenic individuals of African genetic ancestry sampled from the phenotypic extremes: 15 with OP-MG and 10 individuals with control MG (EOM treatment-responsive). Variants were called according to the Genome Analysis Toolkit (GATK) best practice guidelines using the hg38 reference genome. In addition to single variant association analysis, variants were mapped to genes (±200 kb) using VEGAS2 to calculate gene-based test statistics and HLA allele group assignment was inferred through "best-match" alignment of reads against the IMGT/HLA database. While there were no single variant associations that reached genome-wide significance in this exploratory sample, several genes with significant gene-based test statistics and known to be expressed in skeletal muscle had biological functions which converge on muscle atrophy signaling and myosin II function. The closely linked and genes were associated with OP-MG subjects (gene-based < 0.05) and the frequency of a functional A > G SNP (rs9277534) in the 3'UTR, which increases expression, differed between the two groups (-allele 0.30 in OP-MG vs. 0.60 in control MG; = 0.04). Furthermore, we show that rs9277534 is an expression quantitative trait locus in patient-derived myocytes ( < 1 × 10). The application of a SNP to gene to pathway approach to this exploratory WGS dataset of African myasthenic individuals, and comparing dichotomous subphenotypes, resulted in the identification of candidate genes and pathways that may contribute to OP-MG susceptibility. Overall, the hypotheses generated by this work remain to be verified by interrogating candidate gene and pathway expression in patient-derived extraocular muscle.

Citing Articles

Mitochondrial dysfunction in myasthenia gravis: Exploring directions for future immunotherapy? A review.

Chen J, Lu J, Lv Z, Wang B, Zhang S, Xu P Biomol Biomed. 2024; 25(2):346-359.

PMID: 39388705 PMC: 11734830. DOI: 10.17305/bb.2024.11197.


The mutational profile in a South African cohort with inherited neuropathies and spastic paraplegia.

Mahungu A, Steyn E, Floudiotis N, Wilson L, Vandrovcova J, Reilly M Front Neurol. 2023; 14:1239725.

PMID: 37712079 PMC: 10497947. DOI: 10.3389/fneur.2023.1239725.


Analysis of Structural Variants Previously Associated With ALS in Europeans Highlights Genomic Architectural Differences in Africans.

Monnakgotla N, Mahungu A, Heckmann J, Botha G, Mulder N, Wu G Neurol Genet. 2023; 9(4):e200077.

PMID: 37346932 PMC: 10281237. DOI: 10.1212/NXG.0000000000200077.


Mitochondrial bioenergetics in ocular fibroblasts of two myasthenia gravis cases.

Europa T, Nel M, Lebeko M, Heckmann J IBRO Neurosci Rep. 2022; 12:297-302.

PMID: 35746973 PMC: 9210483. DOI: 10.1016/j.ibneur.2022.04.007.


DCAF12 and HSPA1A May Serve as Potential Diagnostic Biomarkers for Myasthenia Gravis.

Nong W, Huang F, Mao F, Lao D, Gong Z, Huang W Biomed Res Int. 2022; 2022:8587273.

PMID: 35655486 PMC: 9155969. DOI: 10.1155/2022/8587273.


References
1.
Porter J, Khanna S, Kaminski H, Rao J, Merriam A, Richmonds C . Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci U S A. 2001; 98(21):12062-7. PMC: 59827. DOI: 10.1073/pnas.211257298. View

2.
McLoon L, Wirtschafter J . Activated satellite cells in extraocular muscles of normal adult monkeys and humans. Invest Ophthalmol Vis Sci. 2003; 44(5):1927-32. PMC: 1796845. DOI: 10.1167/iovs.02-0673. View

3.
Ito M, Nakano T, Erdodi F, Hartshorne D . Myosin phosphatase: structure, regulation and function. Mol Cell Biochem. 2004; 259(1-2):197-209. DOI: 10.1023/b:mcbi.0000021373.14288.00. View

4.
Kaminski H, Li Z, Richmonds C, Lin F, Medof M . Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol. 2004; 189(2):333-42. DOI: 10.1016/j.expneurol.2004.06.005. View

5.
Heckmann J, Owen E, Little F . Myasthenia gravis in South Africans: racial differences in clinical manifestations. Neuromuscul Disord. 2007; 17(11-12):929-34. DOI: 10.1016/j.nmd.2007.07.002. View